Korean Government Accelerates Support For Homegrown Biosimilars
This article was originally published in PharmAsia News
Executive Summary
SEOUL - While South Korea's FDA is getting ready to release its initial version of registration guidelines for biosimilars, the Ministry for Knowledge Economy said it would use public funds to help local pharma and biotech companies to compete in the biosimilar arena
You may also be interested in...
Korean Government Announces Joint Fund To Beef Up Local Pharma Industry
SEOUL - The Korean government is moving to create a KRW2 trillion ($1.7 billion) research and development fund to help local Korean pharma companies develop globally competitive new drugs
Korean Government Announces Joint Fund To Beef Up Local Pharma Industry
SEOUL - The Korean government is moving to create a KRW2 trillion ($1.7 billion) research and development fund to help local Korean pharma companies develop globally competitive new drugs
Korea's Celltrion Signs Deal with Hungary's Egis Pharmaceuticals to Sell Biosimilars In Former Soviet Republic Countries, Eastern Europe
SEOUL - South Korea's Celltrion has signed a deal with Hungary's Egis Pharmaceuticals to sell Celltrion's future biosimilar products in the former Soviet Republic countries and Eastern Union